Paclitaxel (Taxol)

8150  relevant articles (1130 outcomes, 2855 trials/studies) found for this Drug

Taxol; Anzatax; Paxene; 7-epi-Taxol; Bris Taxol; Bristol-Myers Brand of Paclitaxel; Bristol-Myers Squibb Brand of Paclitaxel; Bull Brand of Paclitaxel; Ivax Brand of Paclitaxel; Lemery Brand of Paclitaxel; NSC-125973; Onxol; Paclitaxel, (4 alpha)-Isomer; Praxel; Taxol A; 7 epi Taxol; NSC 125973; NSC125973; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,1-2alpha,12aalpha,12balpha))-

Relationship Network

Drug Context: Research Results

Experts

1.	Markman, Maurie: 25 articles (05/2008 - 05/2002)
2.	Fountzilas, G: 24 articles (05/2008 - 02/2000)
3.	Kosmidis, P: 16 articles (11/2007 - 02/2000)
4.	Bafaloukos, D: 15 articles (05/2008 - 05/2000)
5.	Greco, F Anthony: 15 articles (09/2007 - 01/2002)
6.	Sakamoto, Junichi: 14 articles (11/2008 - 05/2003)
7.	Papadimitriou, C: 14 articles (05/2008 - 05/2000)
8.	Skarlos, D: 14 articles (05/2008 - 02/2000)
9.	Hainsworth, John D: 14 articles (09/2007 - 01/2002)
10.	Beijnen, J H: 14 articles (10/2006 - 01/2000)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2008 - "The development of paclitaxel resistance in tumors is one of the most significant obstacles to successful therapy. " 05/15/2006 - "The development of paclitaxel-resistance in tumors is one of the most significant obstacles to successful therapy. " 04/01/2005 - "The development of resistance to paclitaxel in tumors is one of the most significant obstacles to successful therapy. " 05/15/2002 - "Paclitaxel, an antimicrotubule agent, is highly efficacious in the treatment of adult tumors and is in clinical evaluation in childhood tumors. " 10/01/2001 - "Taxol, one of the most outstanding agents, has been found beneficial in treatment of refractory ovarian, breast and other cancers. " Order ALL the reference details at left...
2.	Breast Neoplasms (Breast Cancer) 09/01/2005 - "Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks." 01/01/1993 - "Taxol is an important new antitumor agent with demonstrated efficacy in ovarian and breast cancer. " 01/01/2007 - "It is therefore concluded that paclitaxel in combination with seal oil demonstrated enhanced cytotoxicity and apoptosis in MCF-7 and MDA-MB-231 cells compared to paclitaxel alone, and the use of seal oil may be beneficial in the treatment of breast cancer." 02/01/2004 - "It may be concluded that the addition of paclitaxel to anthracycline-based therapy resulted in a statistically significant improvement in outcome in patients with ER-negative inflammatory breast cancer." 02/15/2001 - "Significant influences on adoption included use of symposia as a therapy information source, physician experience with paclitaxel to treat late-stage breast cancer, and perceived advantage in efficacy of paclitaxel. " Order ALL the reference details at left...
3.	Ovarian Neoplasms (Ovarian Cancer) 02/01/2009 - "Paclitaxel is used in the first line treatment of ovarian cancer, but acquired resistance represents the most important clinical problem and a major obstacle to a successful therapy. " 09/01/2007 - "Both times, the paclitaxel dramatically improved the ovarian cancer. " 03/01/2004 - "Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian cancer. " 04/01/1996 - "Taxol has been called the best new anticancer agent developed from natural products, showing particular efficacy against ovarian cancer. " 02/15/1995 - "Taxol has been called the best new anticancer agent developed from natural products, showing particular efficacy against ovarian cancer. " Order ALL the reference details at left...
4.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 07/01/2004 - "We believe that using paclitaxel in concurrent chemoradiotherapy regimens may be effective in patients with unresectable, locoregionally advanced non-small cell lung cancer." 12/01/2001 - "CONCLUSION: Paclitaxel administered as a weekly 1-h infusion at a dose of 90 mg/m(2) is a safe and effective therapy for elderly patients with advanced non-small cell lung cancer. " 04/01/1999 - "Several studies have been conducted to assess the safety and efficacy of paclitaxel plus radiation therapy in patients with non-small cell lung cancer (NSCLC) and to assess whether the radiosensitization demonstrated by paclitaxel in vivo can translate into clinical benefit. " 01/01/2000 - "PURPOSE: To evaluate the safety and efficacy of paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC). " 06/01/2008 - "PURPOSE: We report the toxicity profile and pharmacokinetic data of a schedule-dependent chemoradiation regimen using pulsed low-dose paclitaxel for radiosensitization in a Phase I study for inoperable non-small-cell lung cancer. " Order ALL the reference details at left...
5.	Carcinoma (Carcinomatosis) 10/15/2001 - "Treatment of ovarian carcinomas with the antimitotic antitumor drug paclitaxel is highly efficacious. " 04/01/2006 - "CONCLUSION: The significant efficacy of (90)Y-hu3S193 and paclitaxel CMRIT at low radiation doses in this model of breast carcinoma indicates its therapeutic potential and warrants further investigation into this promising therapeutic approach." 02/01/2002 - "NMP-1 and HEY models have significant value in establishing the efficacy of candidate agents, which might address Taxol-resistant human ovarian carcinoma. " 07/01/2006 - "In particular, paclitaxel has been demonstrated to be effective for the treatment of ovarian, breast, and nonsmall cell lung carcinomas. " 11/01/2003 - "Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Carboplatin (JM8)
2.	Paclitaxel (Taxol)
3.	Cisplatin (Platino)
4.	gemcitabine
5.	Doxorubicin (Adriamycin)
6.	docetaxel (Taxotere)
7.	Platinum
8.	Cyclophosphamide (Cytoxan)
9.	Fluorouracil (Carac)
10.	Epirubicin (Ellence)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Stents
4.	Heterologous Transplantation (Xenotransplantation)
5.	Adjuvant Chemotherapy